Connect to other sites within the UBM Medica Network
Higher RT Dose in Pediatric Brain Tumors Limited Vocabulary Development
In children with primary brain tumors who were treated with cranial radiation, cerebral volume and radiation dose may affect the rate of vocabulary development.
Vinblastine First-Line Option for Pediatric Low-Grade Glioma
Vinblastine monotherapy produced outcomes similar to current therapies in children with treatment-naive pediatric low-grade glioma, and had favorable toxicity and quality-of-life profiles.
Deferring Postoperative RT for Pediatric Medulloblastoma Affected Survival
The deferral of postoperative radiotherapy is increasing among children with medulloblastoma, and this deferral of treatment was associated with worse survival.
Brain Function Differs By Medulloblastoma Subtype
Patients with different molecular subtypes of medulloblastoma, a common type of childhood brain tumor, have varying decline in brain function following radiation therapy for their disease.
Insurance Status Affected Glioblastoma Survival
Patients with glioblastoma who were uninsured or who had Medicaid at the time of diagnosis were more likely to be diagnosed with a larger tumor and had shorter survival times.
Gene Underexpression Linked With Poor Glioblastoma Prognosis
The underexpression of one of the homeobox (HOX) genes, HOXA11, is associated with poor prognosis in patients with glioblastoma.
Radiosurgery and Immunotherapy for Melanoma Patients With Brain Metastases
In this video we discuss the use of concurrent immunotherapy and stereotactic radiosurgery for treatment of melanoma brain metastases.
ASCO: No Benefit From Avastin in Newly Diagnosed Glioblastoma
Results of two phase III trials, presented at ASCO, on the addition of bevacizumab (Avastin) to standard therapy in newly diagnosed glioblastoma found that the drug added no benefit.
By clicking Accept, you agree to become a member of the UBM Medica Community.